The 7th China Pharma IP Summit (“CPIPS 2022”) was held in Suzhou from September 21th to 23th. This summit was jointly organized by YIP Events and IP ForeFront with the theme of "New Kinetic Energy Stimulates New Vitality". Lifang & Partners sent an expert team of 5 partners and senior counsels to attend the summit and hosted a special seminar in the afternoon of September 21th on “Practical Issues of IP Due Diligence on Pharmacy”, which features keynote speeches and a roundtable discussion.
With Partner ZHENG Xilin hosting the seminar, WANG Ying, YANG Jian, WU Runzhi and WANG Rui gave keynote speeches, respectively, on the essentials and thorny issues relating to protection of the intellectual property rights of biomedical enterprises and administrative protection approaches. Their speeches are:
WANG Ying: The focus of IP due diligence in various scenarios and the impact on enterprises
YANG Jian: Requirements and difficulties of IP due diligence for biological drugs
WU Runzhi: Requirements and difficulties of IP due diligence for small molecule drugs
WANG Rui: Special concerns of IP due diligence on biomedicine in the Chinese judicial practices
Their practical approach and insightful views were well received.
Dr. YANG Jian then hosted a roundtable discussion. Centering around the objective, current status, and the prospect of IP due diligence on pharmacy, she led a lively conversation with a number of professionals in well-known pharmaceutical companies and investment firms.
Lifang & Partners has paid close attention to IP issues on pharmacy and will provide our clients with excellent transactional and dispute resolution services that combine our in-depth understanding of China’s legal, social and economic development with rich practical experience and a solid understanding of the challenges.